Your session is about to expire
← Back to Search
Other
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
Phase 1
Waitlist Available
Research Sponsored by Cerevel Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours in each period
Awards & highlights
No Placebo-Only Group
Summary
This trial tests CVL-231, a drug for treating psychosis in people with schizophrenia. It works by activating a specific brain receptor to help manage symptoms. The study will also see how different formulations and food affect the drug's performance.
Eligible Conditions
- Schizophrenia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 72 hours in each period
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours in each period
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Secondary: Clinically significant findings in suicidality assessed using the Columbia Suicide-Severity Rating Scale (C-SSRS)
Secondary: Incidence of clinically significant changes in electrocardiogram (ECG) results
Secondary: Incidence of clinically significant changes in vital sign measurements
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part B: Single doses of CVL-231 target release formulation under fasted and fed conditionsExperimental Treatment2 Interventions
Oral Dose
Group II: Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditionsExperimental Treatment4 Interventions
Oral Dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
30 mg CVL-231 as slow-release MR formulation
2021
Completed Phase 1
~20
30 mg CVL-231 Target Release, Fasted
2021
Completed Phase 1
~20
10 mg CVL-231 as IR formulation
2021
Completed Phase 1
~20
30 mg CVL-231 as fast release MR formulation
2021
Completed Phase 1
~20
30 mg CVL-231 as medium release MR formulation
2021
Completed Phase 1
~20
30 mg CVL-231 Target Release, Fed
2021
Completed Phase 1
~20
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Cerevel Therapeutics, LLCLead Sponsor
36 Previous Clinical Trials
5,526 Total Patients Enrolled
7 Trials studying Schizophrenia
2,010 Patients Enrolled for Schizophrenia
Matthew Leoni, MD, MBAStudy DirectorCerevel Therapeutics, LLC
2 Previous Clinical Trials
88 Total Patients Enrolled
1 Trials studying Schizophrenia
15 Patients Enrolled for Schizophrenia